These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1315738)

  • 1. Heparin binding to protein C inhibitor.
    Pratt CW; Church FC
    J Biol Chem; 1992 May; 267(13):8789-94. PubMed ID: 1315738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of three heparin-binding serine proteinase inhibitors.
    Pratt CW; Whinna HC; Church FC
    J Biol Chem; 1992 May; 267(13):8795-801. PubMed ID: 1315739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.
    Van Deerlin VM; Tollefsen DM
    J Biol Chem; 1991 Oct; 266(30):20223-31. PubMed ID: 1939083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition.
    Derechin VM; Blinder MA; Tollefsen DM
    J Biol Chem; 1990 Apr; 265(10):5623-8. PubMed ID: 2138609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II.
    Cooper ST; Rezaie AR; Esmon CT; Church FC
    Thromb Res; 2002 Jul; 107(1-2):67-73. PubMed ID: 12413592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of chymotrypsin by heparin cofactor II.
    Church FC; Noyes CM; Griffith MJ
    Proc Natl Acad Sci U S A; 1985 Oct; 82(19):6431-4. PubMed ID: 3863104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutagenesis of recombinant protein C inhibitor reactive site residues alters target proteinase specificity.
    Phillips JE; Cooper ST; Potter EE; Church FC
    J Biol Chem; 1994 Jun; 269(24):16696-700. PubMed ID: 8206990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General features of the heparin-binding serpins antithrombin, heparin cofactor II and protein C inhibitor.
    Pratt CW; Church FC
    Blood Coagul Fibrinolysis; 1993 Jun; 4(3):479-90. PubMed ID: 8392392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antithrombin P1 residue is important for target proteinase specificity but not for heparin activation of the serpin. Characterization of P1 antithrombin variants with altered proteinase specificity but normal heparin activation.
    Chuang YJ; Swanson R; Raja SM; Bock SC; Olson ST
    Biochemistry; 2001 Jun; 40(22):6670-9. PubMed ID: 11380262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of dysthrombins Quick I and II by heparin cofactor II and antithrombin.
    Phillips JE; Shirk RA; Whinna HC; Henriksen RA; Church FC
    J Biol Chem; 1993 Feb; 268(5):3321-7. PubMed ID: 8429008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
    Blinder MA; Tollefsen DM
    J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the H helix in heparin binding to protein C inhibitor.
    Shirk RA; Elisen MG; Meijers JC; Church FC
    J Biol Chem; 1994 Nov; 269(46):28690-5. PubMed ID: 7961820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspartic acid residues 72 and 75 and tyrosine-sulfate 73 of heparin cofactor II promote intramolecular interactions during glycosaminoglycan binding and thrombin inhibition.
    Mitchell JW; Church FC
    J Biol Chem; 2002 May; 277(22):19823-30. PubMed ID: 11856753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of lysine 173 in heparin binding to heparin cofactor II.
    Whinna HC; Blinder MA; Szewczyk M; Tollefsen DM; Church FC
    J Biol Chem; 1991 May; 266(13):8129-35. PubMed ID: 1902471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced heparin affinity and enhanced conformational stability by binding of a tetradecapeptide corresponding to the P1 to P14 region of the putative reactive bond loop of the inhibitor.
    Björk I; Ylinenjärvi K; Olson ST; Bock PE
    J Biol Chem; 1992 Jan; 267(3):1976-82. PubMed ID: 1730729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.
    Scully MF; Ellis V; Seno N; Kakkar VV
    Biochem J; 1988 Sep; 254(2):547-51. PubMed ID: 2902851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the glycosaminoglycan-binding region of lactoferrin.
    Wu HF; Monroe DM; Church FC
    Arch Biochem Biophys; 1995 Feb; 317(1):85-92. PubMed ID: 7872808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement.
    Olson ST; Björk I; Sheffer R; Craig PA; Shore JD; Choay J
    J Biol Chem; 1992 Jun; 267(18):12528-38. PubMed ID: 1618758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa.
    Danielsson A; Raub E; Lindahl U; Björk I
    J Biol Chem; 1986 Nov; 261(33):15467-73. PubMed ID: 3782075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity.
    Sheehan JP; Wu Q; Tollefsen DM; Sadler JE
    J Biol Chem; 1993 Feb; 268(5):3639-45. PubMed ID: 8429040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.